$ALDX News

Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock

AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection

FDA issues CRL to Aldeyra’s reproxalap drug application

FDA issues CRL to Aldeyra’s reproxalap drug application

HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

Aldeyra Therapeutics Shares Fall Pre-Bell After US FDA Response Cites Lack of Efficacy Data for Dry Eye Drug

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%

Aldeyra Therapeutics shares are trading lower after the company announced that it received a complete response letter from the FDA on replroxalap for the treatment of dry eye disease which cited lack of evidence and inconsistency of study results.

Aldeyra Therapeutics Receives CRL From FDA For NDA Of Reproxalap, Investigational Drug Candidate, For Treatment Of Dry Eye Disease

SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy

Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know

Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?

ATA Creativity Global Among 3 Promising Penny Stocks

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst